Enanta is committed to developing new treatments for viral infections and liver diseases. Enanta has active research and development programs in areas such as respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH), hepatitis B virus (HBV), human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).
If you are a healthcare professional interested in learning more about Enanta’s clinical trials, please contact: Nathalie Adda, MD at nadda@enanta.com.
Learn more about any of our clinical trials described below by clicking the ClinicalTrials.gov. identifier listed below the description of the trial.
Non-Alcoholic Steatohepatitis
A Phase 2b Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects With Liver Biopsy Proven Non-Alcoholic Steatohepatitis (NASH) (ARGON-2)
Clinicaltrials.gov identifier: NCT04378010
A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study of Orally Administered EDP-297 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD), Multiple Ascending Doses (MAD), and the Effect of Food on EDP-297 Pharmacokinetics in Healthy Subjects
ClinicalTrials.gov Identifier: NCT04559126
Respiratory Syncytial Virus
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Ambulatory Adult Subjects (RSVP)
Clinicaltrials.gov identifier: NCT04196101
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of EDP-938 in Hematopoietic Cell Transplant Recipients with Acute RSV Infection and Symptoms of Upper Respiratory Tract Infection (RSVTx)
ClinicalTrials.gov Identifier: NCT04633187
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate EDP-938 in Regimens in Subjects Aged 28 Days to 24 Months Infected with Respiratory Syncytial Virus (RSV) (RSVPEDs to initiate in Q1 2021)